Background {#Sec1}
==========

Prostate cancer (PCa) is the most diagnosed malignancy and the second leading cause of cancer-related deaths among men in Western countries \[[@CR1]\]. Radical prostatectomy (RP) has been shown to have a cancer-specific survival benefit for men with clinically localised PCa \[[@CR2]\]. Although many patients are disease-free after surgery, nearly 30% \[[@CR3]\] of patients still continue to experience biochemical recurrence (BCR). Defined as a detectable prostate-specific antigen (PSA) level following RP in the absence of clinical progression, BCR is the most common pattern of disease relapse \[[@CR4]\]. Patients with BCR have a considerably worse prognosis, often develop metastasis, and can die of the disease \[[@CR3], [@CR4]\]. Therefore, identifying prognostic predictors of BCR after RP to assist clinicians in predicting outcomes for decision making is required.

Numerous nomograms including pathological tumour stage \[[@CR5]\], Gleason's score \[[@CR6]\], seminal vesicle invasion \[[@CR7]\], and lymphatic invasion \[[@CR8]\] have been developed to predict subsequent risk of BCR after RP. Unfortunately, because the collective prognostic value of these factors is unsatisfactory, better biomarkers are urgently needed. Positive surgical margin (PSM) is defined as the histological presence of cancer cells at the inked margin on the RP specimen \[[@CR9]\]. Although PSM is frequently reported in radical prostatectomy series, their clinical relevance remains uncertain despite extensive investigation. A number of studies have demonstrated an association between PSM and BCR \[[@CR5], [@CR10], [@CR11]\], while others have observed insignificant or even contrary correlations \[[@CR12]--[@CR14]\].

Previously, Yossepowitch \[[@CR15]\] systematically reviewed related studies on PSM reporting survival of surgical treatment for patients with PCa. These studies suggested that PSM in PCa should be considered an adverse oncological outcome. Nevertheless, a meta-analysis was not performed because of low-quality evidence and potential risks of bias. A meta-analysis utilises statistical methods to contrast and combine results from multiple studies, increasing the statistical power and reproducibility compared with individual studies \[[@CR16]\]. Hence, to obtain the most conclusive results, we conducted a meta-analysis with high-quality retrospective cohort studies to assess the prognostic value of PSM in BCR.

Methods {#Sec2}
=======

Literature search {#Sec3}
-----------------

This meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A comprehensive search of the literature in PubMed, EMBASE, and Wan Fang databases up to November 2017 was performed using a combined text and MeSH heading search strategy with the following terms: ("prostate cancer" or "prostate AND neoplasms") and ("radical prostatectomy") and ("positive surgical margin") and ("biochemical recurrence" OR "biochemical failure"). In addition, reference lists in the recent reviews, meta-analysis, and included articles were manually searched to identify related articles. The language of the publications was limited to English and Chinese.

Inclusion and exclusion criteria {#Sec4}
--------------------------------

We defined the inclusion and exclusion criteria for study selection at the initiation of the search. The following inclusion criteria were used: (1) included definitive diagnosis of PCa and PSM assessed by pathologists; (2) all patients underwent RP treatment; (3) BCR after RP was defined; (4) the risk of BCR was estimated as hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) or the risk could be calculated from the reported data; and (5) published in English or Chinese. The following exclusion criteria were used: (1) letters, reviews, case reports, editorials, and author responses; (2) non-human studies; (3) studies that did not analyse the outcome after PSM and BCR; (4) studies with duplicated patient populations that had been reported in previous publications; or (5) articles contained elements that were inconsistent with the inclusion criteria.

Data extraction and quality assessment {#Sec5}
--------------------------------------

Two investigators (Zhenlei Zha and Hu Zhao) independently extracted the data from all eligible publications. Any differences among evaluators were resolved by discussion with a third investigator (BinWu). The following data were extracted from the included studies using a standardised data collection protocol (Table [1](#Tab1){ref-type="table"}**,** Table [2](#Tab2){ref-type="table"}): first author's name, year of publication, country, recruitment period, sample size, patient's age, [preoperative](https://www.baidu.com/link?url=Xlv8WJkfKpiczDe_Ss2Ubzs3_fhxnPxQ2oTeNRjvI4p4PECqvMu9Aq2LZJ2KZ-C0H5aYZ1rW1d1hk18FX07RjkkVSqcow3csNtnSnJH25du&wd=&eqid=f81aa271000798e60000000359396105) PSA level, Gleason score, pathological stage, positive percentage of PSM and BCR, definition of BCR, follow-up time, and the HRs (95% CIs) of PSM in univariate or multivariate Cox analyses for BCR. The quality of the eligible studies was evaluated according to the Newcastle--Ottawa Scale (NOS), which include three domains (selection of the study population, comparability of the groups, ascertainment of the outcome). We identified articles of "high quality" as those with NOS scores of 6--9, whereas scores of 0--5 were considered to indicate poor quality.Table 1Primary characteristics of the included studiesAuthorYearCountryNo. of patientsRecruitment periodAge\
(years)p-PSA\
(ng/ml)Follow-up (months)Surgical approachWettstein et al. \[[@CR35]\]2017Switzerland3712008--2015Median (range)\
63 (41--78)Median (range)\
6.79 (0.43--81.4)Median (range)\
28 (1--64)NAXun et al. \[[@CR6]\]2017China1722003--2014Median (IQR)\
68 (62--72)Median (IQR)\
16.1 (10.9--28.3)Median (IQR)\
46.4 (33.4--62.4)NAMeyer et al. \[[@CR36]\]2017Germany9031992--2005Median (IQR)\
63 (59--66)Median (IQR)\
6.4 (4.6--9.0)Median (IQR)\
133 (97--157)NAGandaglia et al. \[[@CR37]\]2017Multi-centred942011--2015Median (IQR)\
64.3 (57.1--68.9)Median (IQR)\
9.7 (5.1--17.5)Median (IQR)\
23.5 (18.7--27.3)Robot-assisted RPShangguan et al. \[[@CR33]\]2016China1722003--2014Median (range)\
68 (62--72)Median (range)\
16.1 (10.9--28.3)Median (IQR)\
46.4 (33.4--62.4)Open and laparoscopic RPZhang et al. \[[@CR34]\]2016China1682006--2011Median (range)\
69 (53--85)Median (range)\
13.31 (4.59--36.12)Median (range)\
68 (7--98)Laparoscopic RPSimon et al. \[[@CR12]\]2016Multi-centres4112001--2013Mean ± SD\
61 ± 6.1NAMedian\
63NASevcenco et al. \[[@CR38]\]2016Multi-centres72052000--2011Median (IQR)\
61 (57--66)Median (IQR)\
6 (4--9)Median (IQR)\
27 (19--48)NAPagano et al. \[[@CR20]\]2016USA1801990--2011Median (range)\
63.7 (58.8--67.6)Median (range)\
9.1 (6.3--17.1)Median (range)\
26.7 (8.8--66)NAMoschini et al. \[[@CR39]\]2016USA10111987--2012NAMedian\
12.0Median\
211.2NAMortezavi et al. \[[@CR40]\]2016Switzerland1001999--2007Mean ± SD\
63.5 ± 6.5Mean ± SD\
9.6 ± 8.3Median (range)\
126 (60--176)Laparoscopic RPMao et al. \[[@CR41]\]2016China1062008--2009Mean (range)\
68.1 (48--83)Mean (range)\
25.1 (3.1--104.3)Median (range)\
69 (8--84)Laparoscopic RPWhalen et al. \[[@CR29]\]2015USA6092005--2011Mean ± SD\
61.2 ± 7.3Mean ± SD\
6.8 ± 6.3Median (range)\
20.5 (1--80)NASong et al. \[[@CR42]\]2015Korea21371988--2011Median (IQR)\
67 (63--71)Median (IQR)\
6.9 (4.7--11.2)Mean (range)\
39.4 (8--1834)NAReeves et al. \[[@CR43]\]2015Australia14792005--2012Median\
62NAMedian\
14NAHashimoto et al. \[[@CR5]\]2015Japan8372006--2013Median (range)\
65 (39--78)Median (range)\
6.9 (3--47.4)Median (range)\
20.5 (1.3--91.3)Robot-assisted RPAlvin et al. \[[@CR44]\]2015Singapore7252003--2013Median (range)\
62 (37--79)Median (range)\
7.9 (0.79--72.9)Mean (range)\
28.5 (6--116)Robot-assisted RPTouijer et al. \[[@CR13]\]2014USA3691988--2010Median (IQR)\
62 (57--66)Median (IQR)\
8 (5--15)Median\
48NARitch et al. \[[@CR45]\]2014USA9792003--2009Median\
62NAMedian\
47Open and robot-assisted RPKang et al. \[[@CR21]\]2014Korea30342004--2011Mean ± SD\
65.9 ± 6.6Mean ± SD\
11.6 ± 12.2Median\
47NAFairey et al. \[[@CR14]\]2014USA2291987--2008Median (range)\
65 (41--83)NAMedian (range)\
174 (2.4--253.2)NATurker et al. \[[@CR46]\]2013Turkey3311993--2009Mean ± SD\
62.79 ± 6.4Mean ± SD\
11.1 ± 10.5Mean ± SD\
29.7 ± 33.2NASammon et al. \[[@CR10]\]2013USA7941993--2010Mean ± SD\
63.4 ± 8.1Mean ± SD\
5.6 ± 3.6Median (IQR)\
26.4(12.2--54.6)NAChen et al. \[[@CR30]\]2013China1522004--2011NANAMedian (range)\
48 (12--87)Laparoscopic RPSooriakumaran et al. \[[@CR11]\]2012Sweden9442002--2006Median (IQR)\
62.2 (58.2--65.8)Median (IQR)\
6.4(4.8--9.0)Median (IQR)\
75.6(67.2--86.4)Robot-assisted RPLu et al. \[[@CR31]\]2012China8941993--1999Median (IQR)\
62 (57--66)Median (IQR)\
6.0 (4.5--8.6)Median (IQR)\
9.9 (6.1--11.3)NAIremashvili et al. \[[@CR47]\]2012USA14442003--2010Mean (range)\
61.3 (56--66.3)Mean (range)\
5.7 (4.5--8.0)Median (range)\
43.2 (3--216)Open and robot-assisted RPConnolly et al. \[[@CR48]\]2012Australia1601988--1997Mean ± SD\
63.1 ± 6.3Median (IQR)\
9.95 (6.0--21.4)Median (IQR)\
26.2 (5.5--37.3)Robot-assisted RPBusch et al. \[[@CR49]\]2012Germany18451999--2007Mean ± SD\
62.0 ± 5.9Median (range)\
26.3 (17.0--42.1)Median (range)\
56 (0--35)Laparoscopic RPBerge et al. \[[@CR50]\]2012Norway5772002--2008Mean (range)\
61.5 (42--76)Mean (range)\
8.4 (0.3--31)Median (range)\
36 (3--72)Laparoscopic RPLee et al. \[[@CR51]\]2011Korea10002003--2009Median (range)\
66 (37--82)Median (range)\
7.8 (0.1--261.8)Mean\
39.4NAAlenda et al. \[[@CR23]\]2011France12481998--2008Mean (range)\
63 (44--78)Mean (range)\
10.9 (0.9--134)Median\
23.4NAFukuhara et al. \[[@CR52]\]2010Japan3642000--2009Median (range)\
66 (52--78)Median (range)\
8.1 (1.7--77.7)Median (range)\
33 (10--109)NACho et al. \[[@CR53]\]2010Korea1712005--2009Mean (range)\
64.4 (49--80)NAMean (range)\
23.3 (2--51)NAAlkhateeb et al. \[[@CR26]\]2010Canada12681992--2008Mean ± SD\
62.0 ± 6.6Median (range)\
6.2 (0.1--65.9)Mean (range)\
78.1 (3--192)NAJeon et al. \[[@CR54]\]2009Korea2371995--2004Mean (range)\
64.5 (44--86)Mean (range)\
11.5 (0.2--98)Median (range)\
21.6 (2--88)NASchroeck et al. \[[@CR55]\]2008USA31941988--2007Median (IQR)\
62.6(57.2--67.9)Median (IQR)\
6.3(4.5--9.6)Median\
31.2NAPavlovich et al. \[[@CR56]\]2008USA5082001--2005Mean ± SD\
57.6 ± 6.7Mean (range)\
6.0 (0.3--27)Median (range)\
12 (2--52)Laparoscopic RPHong et al. \[[@CR57]\]2008Korea3722003--2007Mean (range)\
64.2 (37--72)Mean (range)\
8.7 (0.2--104.2)NANACheng et al. \[[@CR8]\]2005Indiana5041990--1998Mean (range)\
62 (34--80)NAMean (range)\
44 (1.5--144)NAShariat et al. \[[@CR58]\]2004USA6301994--2002Median (range)\
60.9 (40--75)Mean (range)\
6.1 (0.1--99)Median (range)\
21.4 (1--101.3)NA*p-PSA* [preoperative](https://www.baidu.com/link?url=Xlv8WJkfKpiczDe_Ss2Ubzs3_fhxnPxQ2oTeNRjvI4p4PECqvMu9Aq2LZJ2KZ-C0H5aYZ1rW1d1hk18FX07RjkkVSqcow3csNtnSnJH25du&wd=&eqid=f81aa271000798e60000000359396105) prostate-specific antigen, *SD* standard deviation, *IQR* interquartile range, *NA* data not applicableTable 2Tumour characteristics of the included studiesAuthorSpecimen\
GS ≦ 7/˃ 7Staging systemT stage\
1--2/3--4SM+/ SM−No. of BCR (%)Definition of BCRWettstein et al. \[[@CR35]\]292 /79WHO/ISUP 2016263/108133/23849 (13.2%)Rising and verified PSA levels \> 0.1 ng/mlXun et al. \[[@CR6]\]131/41TNM 2002NA62/11080 (46.5%)The date of the first PSA elevated to 0.2 ng/mlMeyer et al. \[[@CR36]\]879/24TNM 2002903/037/206137(15.2%)PSA level of ≧ 0.2 ng/ml and rising after RPGandaglia et al. \[[@CR37]\]55/39TNM 200222/7230/6424 (25.5%)Two consecutive increases in PSA ≧ 0.2 ng/mlShangguan et al. \[[@CR33]\]131/41NANA62/110NATwo consecutive increases in PSA ≧ 0.2 ng/mlZhang et al. \[[@CR34]\]136/32TNM 2012NA30/138NAFirst PSA elevated to 0.2 ng/mlSimon et al. \[[@CR12]\]368/43NANA353/5870 (17%)Single PSA concentration of \> 0.2, two concentrations at 0.2 ng/mlSevcenco et al. \[[@CR38]\]6645/560TNM 2009NA6137/1074798 (11.1%)Two consecutive increases in PSA ≧ 0.2 ng/mlPagano et al. \[[@CR20]\]90/90TNM 2002NA74/106120 (66.5%)Two postoperative PSA values of ≧ 0.2 ng/mlMoschini et al. \[[@CR39]\]647/364NA355/657566/445697 (69%)PSA 0.4 ng/ml or greaterMortezavi et al. \[[@CR40]\]86/14NA79/2125/7512 (12%)Two consecutive increases in PSA ≧ 0.2 ng/mlMao et al. \[[@CR41]\]78/28TNM 200263/4320/8631 (29.2%)Two consecutive increases in PSA ≧ 0.2 ng/mlWhalen et al. \[[@CR29]\]516/93TNM 1997435/174483/12673 (12%)Two consecutive increases in PSA ≧ 0.2 ng/mlSong et al. \[[@CR42]\]1722/415NA1899/2482132/13,433466 (21.8%)Greater than 0.2 ng/mlReeves et al. \[[@CR43]\]1306/142NA1042/454390/1089238 (20.5%)Greater than 0.2 ng/mlHashimoto et al. \[[@CR5]\]634/373WHO 2004677/160243/594102 (12.2%)Two consecutive increases in PSA ≧ 0.2 ng/mlAlvin et al. \[[@CR44]\]663/58TNM 2010497/228311/414104 (14%)Two consecutive increases in PSA ≧ 0.2 ng/mlTouijer et al. \[[@CR13]\]184/185TNM 201046/323138/231201 (54%)PSA ≧ 0.1 ng/ml with confirmatory riseRitch et al. \[[@CR45]\]783/196TNM 2002955/24335/644317 (32.4%)Greater than 0.2 ng/mlKang et al. \[[@CR21]\]2575/459TNM 2009NA974/2060NAA serum PSA value of 0.4 ng/ml or greater after RPFairey et al. \[[@CR14]\]133/96TNM 20020/229105/12483 (36.2%)Detectable PSA (ng/ml) followed by two consecutive confirmatory (1988--1994: PSA ≧ 0.3; 1995--2005: PSA ≧ 0.05; 2006--present: PSA ≧ 0.03)Turker et al. \[[@CR46]\]167/164TNM 1994NA80/25170 (21%)Higher than 0.2 ng/ml on 2 separate measurements 1 month apartSammon et al. \[[@CR10]\]760/34AJCC 2002592/202162/632107 (13.5%)Two consecutive increases in PSA ≧ 0.2 ng/mlChen et al. \[[@CR30]\]109/43NA0/15227/12580 (52.6%)Two consecutive increases in PSA ≧ 0.2 ng/mlSooriakumaran et al. \[[@CR11]\]900/44NA651/230194/704135 (15.2%)Greater than 0.2 ng/mlLu et al. \[[@CR31]\]796/98TNM 2010703/191250/644277 (31%)PSA ≧ 0.1 ng/ml with confirmatory riseIremashvili et al. \[[@CR47]\]1286/258NANA479/965210 (15%)Greater than 0.2 ng/mlConnolly et al. \[[@CR48]\]95/65NA65/9560/10088 (55%)Greater than 0.2 ng/mlBusch et al. \[[@CR49]\]1538/307NA1802/9537/1308450 (24.4%)PSA ≧ 0.1 ng/ml with confirmatory riseBerge et al. \[[@CR50]\]553/24TNM 2002441/136168/40991 (16%)Two consecutive increases in PSA ≧ 0.2 ng/mlLee et al. \[[@CR51]\]236/764NANA337/66399 (9.9%)Two consecutive increases in PSA ≧ 0.2 ng/mlAlenda et al. \[[@CR23]\]1248/0NANA400/843176 (16.9%)PSA \> 0.2 ng/mLFukuhara et al. \[[@CR52]\]332/32TNM 2002275/89157/20766 (18.1%)Two consecutive increases in PSA ≧ 0.2 ng/mlCho et al. \[[@CR53]\]153/14TNM 2002126/4558/10915 (8.8%)A serum PSA value of 0.4 ng/ml or greater after RPAlkhateeb et al. \[[@CR26]\]1159/109NA853/415264/1004NAA serum PSA value of 0.4 ng/ml or greater after RPJeon et al. \[[@CR54]\]190/45TNM 2002145/9286/15167 (28.3%)Two consecutive increases in PSA ≧ 0.2 ng/mlSchroeck et al. \[[@CR55]\]2855/359NA1991/1166982/2212706 (25.7%)Greater than 0.2 ng/mlPavlovich et al. \[[@CR56]\]494/14TNM 2002416/9269/439102 (20%)Two consecutive increases in PSA ≧ 0.2 ng/mlHong et al. \[[@CR57]\]361/11TNM 2002371/046/326NAFirst value greater than 0.2 ng/mlCheng et al. \[[@CR8]\]410/94TNM 1997348/156174/330157 (21.2%)Two consecutive increases in PSA ≧ 0.1 ng/mlShariat et al. \[[@CR58]\]565/65TNM 1997NA179/45180 (12.7%)First value greater than 0.2 ng/ml*GS* Gleason score, *SM+/SM* surgical margin positive/surgical margin negative, *BCR* biochemical recurrence, *NA* data not applicable

Statistical analyses {#Sec6}
--------------------

All statistical analyses in this meta-analysis were performed by Stata 12.0 software (Stat Corp, College Station, TX, USA). The association between PSM and BCR outcome was presented as summary relative risk estimates (SRREs) and 95% CIs. Heterogeneity between studies was calculated by the chi-square-based *Q* test and *I*^*2*^. A value of *p* \< 0.10 or *I*^*2*^ \> 50% was considered as statistically significant heterogeneity. A random-effects model was used if heterogeneity was significant, and otherwise, a fixed-effects model was used. Sensitivity analysis was used to estimate the reliability of the pooled results via the sequential omission of each study. Subgroup analysis was performed to check whether the pooled HR was influenced by the region, publication year, mean age, sample size, mean preoperative PSA (p-PSA), median follow-up, and the cut-off value for BCR. To assess the stability of the combined HR, sensitivity analysis was performed by removing individual studies from the meta-analysis. Publication bias was assessed by funnel plots and was statistically determined by Egger's linear regression. Statistical significance was defined as a two-tailed value of *p* \< 0.05, except for the heterogeneity tests.

Results {#Sec7}
=======

Literature search and study characteristics {#Sec8}
-------------------------------------------

The full process of the systematic literature review is shown in Fig. [1](#Fig1){ref-type="fig"}**.** In accordance with the PRISMA search strategy, 1048 relevant studies were initially identified. After carefully reading each article, 780 studies were excluded for the following reasons: duplicates, letters, or reviews; or contained no evaluated margin status and focus on BCR. After the remaining studies (*n* = 268) were reviewed, additional studies were excluded because certain cohorts were studied more than once or relevant data were lacking. [Forty-one](http://dict.cn/forty-one) high-quality retrospective studies comprising 37,928 patients (94--3294 per study) were ultimately included in the meta-analysis.Fig. 1Flow diagram of the study selection process for this meta-analysis

The primary characteristics of the included studies are summarised in Table [1](#Tab1){ref-type="table"}**.** All studies were published between 2004 and 2017. Of these, 19 studies were conducted in an Asian country, and 12 were conducted in North America; the rest were conducted in Europe (7) or in multiple countries (3). The median follow-up period of the studies ranged from 14 to 174 months. All included studies were published in English, except for two that were in Chinese. Of all of the studies, 8 used laparoscopic RP, 7 used robot-assisted RP, and 3 used open RP. BCR was defined using different cut-off values (0.1 ng/ml, 0.2 ng/ml, 0.4 ng/ml) among the included studies, and the incidence of BCR after RP ranged from 8.8 to 66.5% according to the reported values (Table [2](#Tab2){ref-type="table"}). NOS \[[@CR17]\] was applied to assess the quality of the included studies, and the results showed that all of the studies were of high quality with an NOS score ≥ 7. (Additional file [1](#MOESM1){ref-type="media"}: Table S1).

Meta-analysis {#Sec9}
-------------

The forest plots of the meta-analysis in our study demonstrated that PSM was associated with poorer BCR in RP patients by univariate analysis (random-effects model, pooled HR = 1.56; 95% CI 1.46, 1.66; *p* \< 0.001; Fig. [2](#Fig2){ref-type="fig"}) and multivariate analysis (random-effects model, pooled HR = 1.35; 95% CI 1.27, 1.43; *p* \< 0.001; Fig. [3](#Fig3){ref-type="fig"}). Given the large heterogeneity between the studies, subgroup analyses were performed by region, publication year, mean age, sample size, mean preoperative PSA (p-PSA), median follow-up, and the cut-off value for BCR. Although no significant modifiers accounting for the inter-study heterogeneity were detected, the results of subgroup analyses were consistent with the primary findings (Table [3](#Tab3){ref-type="table"}).Fig. 2Forest plots of the association between PSM and BCR risk in the stratification analysis by univariate modeFig. 3Forest plots of the association between PSM and BCR risk in the stratification analysis by multivariate modeTable 3Overall analyses and subgroup analyses for the included studiesAnalysis specificationNo. of studiesStudy heterogeneityEffects modelPooled HR (95% CI)*p* value*I*^2^ (%)*p* ~heterogeneity~Univariate analysis (BCR) Overall2570.9\< 0.001Random1.56 (1.46,1.66)\< 0.001 Geographical region  Asia1272.1\< 0.001Random1.61 (1.43,182)\< 0.001  Europe and North America1270.8\< 0.001Random1.50 (1.37,1.65)\< 0.001 Date of publication  ≥ 20141381.8\< 0.001Random1.52 (1.36,1.70)\< 0.001  \< 20141218.50.262Fixed1.61 (1.52,1.71)\< 0.001 Mean age (years)  ≥ 64984\< 0.001Random1.62 (1.34,1.97)\< 0.001  \< 641555.60.005Random1.54 (1.45,1.64)\< 0.001 Sample size (cases)  ≥ 5001040.10.09Random1.61 (1.52,1.70)\< 0.001  \< 5001576.9\< 0.001Random1.51 (1.33,1.71)\< 0.001 Mean p-PSA (ng/ml)  ≥ 10781\< 0.001Random1.65 (1.38,1.97)\< 0.001  \< 101458.50.003Random1.59 (1.48,1.71)\< 0.001 Median follow-up  ≥ 36 months1177.1\< 0.001Random1.49 (1.33,1.67)\< 0.001  \< 36 months1459.80.002Random1.61 (1.49,1.74)\< 0.001 BCR (ng/ml)  Cutoff value 0.1400.775Fixed1.61 (1.49,1.72)\< 0.001  Cutoff value 0.22072\< 0.001Random1.58 (1.46,1.70)\< 0.001  Cutoff value 0.41----------Multivariate analysis (BCR) Overall3279.2\< 0.001Random1.35 (1.27,1.43)\< 0.001 Geographical region  Asia1467\< 0.001Random1.42 (1.29,1.55)\< 0.001  Europe and North America1584.7\< 0.001Random1.31 (1.19,1.43)\< 0.001  Multi-centred371.90.029Random1.33 (1.00,1.78)0.053 Date of publication  ≥ 20141682.9\< 0.001Random1.27 (1.17,1.39)\< 0.001  \< 20141667.2\< 0.001Random1.44 (1.32,1.56)\< 0.001 Mean age (years)  ≥ 64862.50.009Random1.56 (1.32,1.85)\< 0.001  \< 642281.5\< 0.001Random1.33 (1.24,1.43)\< 0.001 Sample size (cases)  ≥ 5001877.1\< 0.001Random1.40 (1.32,1.49)\< 0.001  \< 5001476.8\< 0.001Random1.28 (1.12,1.47)\< 0.001 Mean p-PSA (ng/ml)  ≥ 10780.8\< 0.001Random1.36 (1.22,1.57)\< 0.001  \< 101979\< 0.001Random1.35 (1.24,1.48)\< 0.001 Median follow-up  ≥ 36 months1679.6\< 0.001Random1.36 (1.24,1.46)\< 0.001  \< 36 months1579.8\< 0.001Random1.34 (1.21,1.47)\< 0.001 BCR (ng/ml)  Cutoff value 0.1587.7\< 0.001Random1.22 (1.01,1.48)0.044  Cutoff value 0.22371.3\< 0.001Random1.39 (1.30,1.48)\< 0.001  Cutoff value 0.4482.20.001Random1.34 (1.15,1.57)\< 0.001

The sensitivity analysis and publication bias {#Sec10}
---------------------------------------------

With a sensitivity analysis, the overall significance did not change when any single study was omitted. The summary relative risk estimate (SRRE) for BCR ranged from 1.52 (95% CI, 1.44--1.62) to 1.58 (95% CI, 148--1.68) (Fig. [4a](#Fig4){ref-type="fig"}) in univariate analysis and 1.34 (95% CI, 1.26--1.42) to 1.37 (95% CI, 1.29--1.45) (Fig. [4b](#Fig4){ref-type="fig"}) in multivariate analysis. These results indicated that the findings were reliable and robust. To test for publication bias, Egger's linear regression was performed. No significant publication bias was detected between these studies regarding HR of BCR in univariate analysis (p-Begg = 0.971; Fig. [5a](#Fig5){ref-type="fig"}) and multivariate analysis (p-Begg = 0.401; Fig. [5b](#Fig5){ref-type="fig"}), respectively.Fig. 4Sensitivity analysis of the association between PSM and BCR risk in PCa patients. **a** Univariate analysis mode. **b** Multivariate analysis modeFig. 5Funnel plots and Begg's tests for the evaluation of potential publication bias. **a** Univariate analysis mode. **b** Multivariate analysis mode

Discussion {#Sec11}
==========

With the increased public awareness and wide use of PSA-based screening, the number of patients diagnosed with PCa annually has been increasing \[[@CR6]\]. Because RP provides superior cancer control and functional outcomes, this surgery has become a standard first-line treatment for eligible patients \[[@CR18]\]. However, despite various advances in surgical technology, BCR has been reported in approximately 25--35% patients after RP and even more patients with intermediate--high risk \[[@CR19]\]. Because BCR reportedly leads to distant metastasis and cancer death \[[@CR20]\], it is necessary for men with BCR to undergo salvage radiation or hormonal therapy \[[@CR11]\]. Therefore, identifying modifiable factors that affect the progression of BCR may help physicians in the selection of patients who are more likely to benefit from adjuvant multimodal therapy.

A number of nomograms have been developed to predict BCR after RP using either preoperative or postoperative variables \[[@CR21]\]. Several clinical and pathologic factors have been included in these models, most of which cannot be altered by the treating physician (preoperative PSA \[[@CR22]\], pathological T stage \[[@CR5]\], pathological Gleason score \[[@CR23]\]). The D'Amico risk stratification scheme \[[@CR20]\] and Cancer of the Prostate Risk Assessment (CAPRA) score \[[@CR24]\] have also been adopted in the urological community to predict the probability of BCR. Although these nomograms have been internationally validated, unfortunately, only a small number of them have predicted the probability of 5-year BCR with more than 70% accuracy \[[@CR25]\]. Thus, efforts to improve existing outcome prediction tools for PCa are always encouraged.

PSM is a frequent situation encountered after radical prostatectomy (RP) for localised PCa with an occurrence ranging from 6 to 41% \[[@CR9], [@CR26], [@CR27]\]. The incidence of PSM depends on various factors, including tumour biology, patient characteristics, pathological assessment method, and surgical technique \[[@CR28]\]. We reported an overall PSM rate of 45.7% (17,339/37,928), which was slightly higher than other large series. Because the goal of surgical procedures is the complete removal of the tumour, the presence of PSM after RP is considered to be an adverse outcome associated with failure of the surgery to cure the PCa. However, the effects of PSM on clinical outcomes and the risk of BCR are still unclear. Several studies concluded that a PSM is an independent factor of BCR in patients with PCa after RP \[[@CR11], [@CR29]--[@CR31]\]. However, not all patients with PSM show recurrence according to other studies \[[@CR27], [@CR28], [@CR32]\]. Moreover, several reports showed that the effect of PSMs on prognosis depends on certain clinical and pathological features of the disease \[[@CR26]\].

To the best of our knowledge, this study is the most up-to-date and informative meta-analysis on the association between PSM and BCR risk. The results obtained in our meta-analysis are in line with the previous systematic review by Yossepowitch et al. In addition, our study presented a series of advancements in comparison with previous studies. First, we included more eligible studies with high quality. The search by Yossepowitch et al. included studies up to 2013. However, our search included 21 additional studies published from 2014 to 2017, thereby improving the evaluation on the effect and enabling more subgroup analyses. In addition, the studies retrieved for our analysis were not limited to English; two Chinese articles \[[@CR33], [@CR34]\] also met the criteria for inclusion. Similar to Yossepowitch et al., we identified a significant relationship between PSM and BCR in RP. However, we also found that the pooled result of PSM had a large heterogeneity in both univariate (*I*^*2*^ = 70.9%) and multivariate (*I*^*2*^ = 79.2%) analyses. Even though the cut-offs varied among the included studies (0.1 ng/ml, 0.2 ng/ml, 0.4 ng/ml), the subgroup analyses achieved results similar to both univariate and multivariate analyses (Table [3](#Tab3){ref-type="table"}). Meanwhile, the sensitivity analysis of our study revealed that the omission of each study did not have a significant impact on the merged value of HR.

However, several limitations of this study should be considered. First and foremost, all included studies were retrospective; therefore, the data extracted from those studies may have led to potential inherent bias. Second, the criteria to determine the presence of PSM in the pathological specimen were inconsistent in the included studies, which may have potentially contributed to heterogeneity. Thus, rigorous morphological criteria should be established to standardise the diagnosis of PSM. Third, substantial heterogeneity was observed in the meta-analysis, and although we used the random-effects model according to heterogeneity, it still existed in our studies. Moreover, from the subgroup analyses, we believed that the heterogeneity was caused by differences in factors such as patient and tumour characteristics. Finally, studies with negative results tend to be unsubmitted or unpublished; grey literature was not included, meaning that language bias may have been present in this study.

Conclusions {#Sec12}
===========

In conclusion, this meta-analysis demonstrates that PSM has a detrimental effect on BCR risk in patients with PCa after RP and could therefore be considered to be an independent prognostic factor of BCR. Due to PSM's excellent feasibility and low cost, this method should be more widely employed for BCR risk stratification and BCR prediction in patients with PCa. Given the inherent limitations of retrospective studies, further research is warranted, preferably with a longer follow-up period, to elucidate the potential role of PSM in influencing BCR risk.
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